OxyContin maker Perdue Pharma loses bid to delay opioid epidemic trial


by   |  VIEW 235
OxyContin maker Perdue Pharma loses bid to delay opioid epidemic trial

On Friday, the 8th of March 2019, the OxyContin maker, Perdue Pharma, a privately held pharmaceutical, headquartered in Stanford, Connecticut, alongside two other drug makers lost a legal hearing to delay a breakthrough opioid epidemic trial scheduled for May in a multi-billion lawsuit by the attorney general of Oklahoma, accusing the pharmaceuticals of aiding in an opioid abuse and overdose across the state.

Although the decision of Cleveland County District Judge, Thad Balkman had widely been considering as a landmark victory for the state of Oklahoma, yet one of the lawyers had been quoted saying that Purdue had threatened to file for bankruptcy protection rather than facing 2,000 national lawsuits.

During the hearing in Norman, Oklahoma, the lawyer for the state, Reggi Whitten said, “This case needs to get to trial because people are dying every day.

Never the less, a media report last week revealed that ahead of a tormenting trial and accusation of aiding abuse alongside overdose, the Perdue Pharma LP, owned by a wealthy Sackler family, had been exploring the options of filing Chapter 11 bankruptcy protection, which would allow the drug maker to address liabilities as well as to halt the case.